enzyme immunoassay with batch procedure suffers from interference by IgA, present in serum in much greater concentrations than SIgA. We describe here a practical enzyme immunoassay for SIgA in human serum in which interfering IgA is removed by passage through a small column of anti-human IgA antibody immobilized on Sepharose 4B.
Materials and Methods

Materials
We used de-ionized water throughout. Buffer G. Sodium phosphate buffer (10 mmol/L, pH 7) containing per liter, 0.3 mol of NaCI, 1 mmol of MgCl2, 1 g of bovine serum albumin (Cohn Fraction V; Armour Pharmaceutical Co., Chicago, IL), 5 g of digested gelatin, and 1 g of NaN3. The digested gelatin was prepared by the treatment of gelatin (Difco Laboratories, Detroit, MI) with protease T1 (Amano Pharmaceutical Co., Nagoya, Japan) as described previously (8) .
Antigens. SIgA from human colostrum (purity approx. 96%) was obtained from Behringwerke AG, Marburg, F.R.G., and human IgA and 1gM (substantially free of other immunoglobulins) were from Green Cross Co., Osaka, Japan. Human SC purified from human colostrum according to the method of Kobayashi (9) showed a single band in sodium dodecyl sulfate gel electrophoresis. Concentrations of purified SC, SIgA, IgA, and 1gM were estimated from their respective absorptivities 
Antibodies.
Rabbit antiserum
to human SC was obtained from Behringwerke AG, and rabbit antiserum to human IgA (specific to a-chain) was from Medical and Biological Laboratories, Nagoya, Japan. The IgG fractions were isolated from the antisera by precipitation with (NH4)2SO4, dialysis, and chromatography on DEAE-cellulose (11). SC)IgG fractions with pepsin, were reduced with 2-mercaptoethylamine and coupled to f-D-galactosidase (EC 3.2.1.23, from Escherichia coli; Boehringer Mannheim, Mannheim, F.R.G.) by use of N,N'-o-phenylenedimaleimide (12) . The amounts of the conjugate were expressed as units of f-D-galactosidase activity, and 1 U of activity was defined as that which hydrolyzed 1 mol of substrate per minute under the conditions described below.
Anti
Procedures
Measurement of f3-D-galactosidase activity.
One milliliter of the enzyme solution (pH 7) was preincubated at 37 #{176}C for 5 mm, and the reaction was then started by adding 0.25 mL of a 4.5 g/L solution of o-nitrophenyl-fl-D-galactoside (Wako Pure Chemical Industries, Ltd., Osaka, Japan). After incubation at 37 #{176}C for 20 mm, the reaction was stopped by adding 0.25 mL of 1 mol/L sodium carbonate. The absorbance was measured at 420 nm. Enzyme activity was calculated from the molar absorptivity of o-nitrophenyl (21 300) at 420 nm (13) and the dilution factor.
Enzyme immunoassay for SIgA. Samples of 0.1 mL of buffer G containing standard SIgA or 0.1 mL of sample serum diluted 100-fold with buffer G were mixed with 0.5 mL of
(20 U/L, in buffer G) and incubated at 37 #{176}C for 2 h. Then 0.5 mL of the reaction mixture was applied at room temperature (25 #{176}C) to a 4 X 8 mm column (with a funnel-shaped buffer reservoir on the top) ( Figure 1 ) packed with anti-IgA antibody immobilized on Sepharose and equilibrated with buffer G at a flow rate of 3 mL/h. The column was washed twice with 1 mL of buffer G. Then 0.1 mL of o-nitrophenyl-13-D-galactoside, 33 mmol/L, dissolved in buffer G, was applied to the column and the enzyme reaction was carried out at room temperature overnight.
The reaction was stopped by washing the column with 1 mL of 80 mmol/L sodium carbonate. The 1-mL eluate, which contained o-nitrophenol (i.e., the product of enzyme reaction), was diluted with 1.5 mL of 80 mmol/L sodium carbonate and its absorbance measured at 420 nm.
Results
The standard curve of the assay for SIgA and the cross reactivities of IgA, 1gM, and SC are shown in Figure 2 . The minimum detectable amount of SIgA was 3 ng per assay tube. A dose-response of bound 13-D-galactosidase activity was observed between 3 and 1000 ng of SIgA. We observed little increase in $-D-galactosidase activity bound when IgA, 1gM, or SC was substituted for SIgA in the assay.
To find an optimum serum volume applicable to the im- munoassay, we investigated the effect of serum volume on the assay with three different sera. We incubated 0.1 mL of serum diluted 10-to 200-fold with buffer G with (anti-SC)Fab'-3-D-galactosidase conjugate and applied the mixture to the column described above. As shown in Figure 3 , the relationship between SIgA concentration (ng/tube) and serum volume was linear at serum volumes less than 3 sL. Therefore, we used 1 sL of serum in the assay of SIgA because the IgA and SC in 1 tL of serum did not interfere with the assay.
To estimate analytical recovery of SIgA, we assayed three sera containing 5-10 mg of SIgA per liter. Each sample was assayed in duplicate with and without added SIgA (30 or 60 mg/L); the respective recoveries were 92.7 (SD 7.7) % and 97.8 (SD 8.5) %. The precision of assay for SIgA was estimated by assaying three sera eight times in one assay (within-run) or in duplicate in seven consecutive assays (between-run). The coefficients of variation in both assays were less than 10% (Table 1) . 
Discussion
The column enzyme immunoassay for SIgA described here is practical and simple to perform. The colorimetric assay of f3-D-galactosidase activity in the column provides a sensitive and specific determination of serum SIgA without interferences by IgA, 1gM, and SC in the samples under the conditions cited. The anti-SC antiserum for preparing the conjugate must be specific without any cross reaction with IgA. If there is cross reactivity, the conjugate should be passed through a column of IgA-immobilized Sepharose 4B. It is preferable to use both antisera (to SC and a-chain) produced in the same animal species to prevent interference from cross-species immunological reaction. The anti-IgA immobilized on Sepharose was stable for at least six months (at 4 #{176}C), the (anti-SC)Fab'-13-D-galactosidase conjugate for one year (at 4 #{176}C).
Serum rheumatoid factor may cross react in the present assay, as a result of recognition of immobilized rabbit IgG (11) .
Concentrations of serum SIgA in healthy individuals were less than 10 mg/L, comparable with the values reported by Thompson and Asquith (5) . The high concentrations of SIgA in serum from patients with carcinoma or with other diseases agree with previous reports by Klein et al. (2) , and Thompson and Asquith (5) . In some immune diseases, however, apparent high concentrations of serum SIgA may result from the cross reaction of rheumatoid factor as mentioned above. The physiological role of serum SIgA, including the mechanism of its increase in patients, remains to be clarified.
